Insider Selling: Agios Pharmaceuticals (NASDAQ:AGIO) Insider Sells 8,546 Shares of Stock

Key Points

• Agios Pharmaceuticals insider Theodore James Jr. Washburn sold 8,546 shares for a total of $315,091.02, representing a 90.78% decrease in his position, leaving him with only 868 shares.
• The company's recent earnings report showed a loss of $1.93 earnings per share, missing estimates, while revenue was reported at $12.50 million, beating expectations.
• Brokerage firms have issued mixed ratings on Agios, with a consensus target price of $56.00, as analysts maintain a moderate buy rating amidst a backdrop of decreased price objectives from some firms.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) insider Theodore James Jr. Washburn sold 8,546 shares of Agios Pharmaceuticals stock in a transaction on Friday, September 5th. The shares were sold at an average price of $36.87, for a total value of $315,091.02. Following the transaction, the insider owned 868 shares of the company's stock, valued at $32,003.16. The trade was a 90.78% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Agios Pharmaceuticals Trading Up 0.8%

NASDAQ:AGIO traded up $0.28 during trading hours on Friday, reaching $36.78. 603,418 shares of the company traded hands, compared to its average volume of 751,284. The business's 50-day moving average price is $37.71 and its two-hundred day moving average price is $33.25. The stock has a market capitalization of $2.14 billion, a P/E ratio of 3.34 and a beta of 0.87. Agios Pharmaceuticals, Inc. has a 1 year low of $23.42 and a 1 year high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported ($1.93) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.74) by ($0.19). The company had revenue of $12.50 million for the quarter, compared to analysts' expectations of $9.46 million. Agios Pharmaceuticals had a net margin of 1,590.42% and a negative return on equity of 3.49%. As a group, equities analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current year.

Institutional Trading of Agios Pharmaceuticals

Large investors have recently modified their holdings of the company. GF Fund Management CO. LTD. bought a new stake in shares of Agios Pharmaceuticals in the fourth quarter worth $39,000. NewEdge Advisors LLC bought a new stake in shares of Agios Pharmaceuticals in the first quarter worth $40,000. CWM LLC grew its holdings in shares of Agios Pharmaceuticals by 150.2% in the first quarter. CWM LLC now owns 1,659 shares of the biopharmaceutical company's stock worth $49,000 after acquiring an additional 996 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Agios Pharmaceuticals by 16.7% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,237 shares of the biopharmaceutical company's stock worth $74,000 after acquiring an additional 320 shares during the period. Finally, PNC Financial Services Group Inc. grew its holdings in shares of Agios Pharmaceuticals by 16.2% in the first quarter. PNC Financial Services Group Inc. now owns 3,582 shares of the biopharmaceutical company's stock worth $105,000 after acquiring an additional 499 shares during the period.

Analysts Set New Price Targets

AGIO has been the subject of a number of research analyst reports. Bank of America reduced their target price on Agios Pharmaceuticals from $52.00 to $51.00 and set a "buy" rating for the company in a report on Tuesday, July 22nd. Scotiabank reduced their target price on Agios Pharmaceuticals from $71.00 to $65.00 and set a "sector outperform" rating for the company in a report on Monday, July 28th. Wall Street Zen lowered Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Monday, May 19th. Finally, HC Wainwright reissued a "buy" rating and issued a $56.00 target price on shares of Agios Pharmaceuticals in a report on Thursday, September 4th. Six investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, Agios Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $56.00.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.